Polycystin-1 C-Terminus Regulates Protein Synthesis-Related Pathways in Cardiomyocytes

This study demonstrates that the sarcomere-associated C-terminus of polycystin-1 in cardiomyocytes activates a Gi/o-independent PI3K-Akt-mTOR-S6K1-S6 signaling axis to drive ribosome biogenesis and protein synthesis, thereby promoting cardiomyocyte growth without inducing a canonical hypertrophic gene program.

The Gist

Imagine your heart as a busy, high-performance factory. When the heart has to work harder (like during high blood pressure), the factory needs to build more machinery to keep up. This process is called cardiac hypertrophy. To build more machinery, the factory needs to ramp up its "construction crew" (protein synthesis).

For a long time, scientists knew the factory needed to build more, but they didn't fully understand who was the foreman telling the crew to start working when the heart felt the physical stress of stretching.

This paper introduces a key foreman named Polycystin-1 (PC1). Specifically, the researchers focused on the "tail" end of this protein (PC1-CT). Here is what they discovered, explained simply:

1. The Foreman's New Office Location

Previously, scientists thought this "tail" of the protein floated around the cell's control center or the membrane. But in this study, using human heart cells grown in a lab, they found something surprising.

The Analogy: Imagine a construction foreman who usually sits in the main office. The researchers found that this foreman actually has a specific desk right on the assembly line itself.

• They saw that the PC1 tail sits in a striped pattern, right between the "beams" of the heart muscle's internal skeleton (the sarcomere).
• It's like the foreman is standing directly on the factory floor, watching the workers (the muscle fibers) stretch and contract, ready to give orders immediately.

2. The "Build More" Signal

When the researchers artificially added more of this "tail" to the heart cells, the cells didn't just get bigger in a messy way. Instead, they started a very specific type of growth.

The Analogy: Think of a factory that needs to expand.

• Old Theory: The foreman would shout, "Change the whole factory layout! Build new rooms!" (This would be the "classic" heart disease response).
• New Finding: The PC1 tail didn't change the factory layout. Instead, it went straight to the supply room and said, "We need more raw materials! Order more bricks, more cement, and more blueprints!"
• Scientifically, this means the cells turned on genes related to making ribosomes (the machines that build proteins) and processing RNA (the blueprints). They didn't turn on the "disease" genes, just the "growth and production" genes.

3. The Secret Handshake (The Signaling Pathway)

How does the foreman send the message? The researchers traced the signal like a detective following a trail of breadcrumbs.

The Analogy: The PC1 tail pulls a specific lever that activates a chain reaction:

1. It flips a switch called PI3K.
2. This wakes up a manager named Akt.
3. Akt then tells the mTOR system (the main production boss) to get moving.
4. Crucially, mTOR tells a specific worker, S6, to start building proteins.

The Twist: The researchers found that this chain reaction is very specific. It's like a dedicated express lane.

• They tried to block different roads to see which one the signal used.
• Blocking the "MEK road" (a different highway) did nothing.
• Blocking the "PI3K road" stopped the whole process.
• They also found that this signal doesn't rely on the usual "G-protein" messengers that other parts of the cell use. It's a unique, direct line from the muscle skeleton to the protein factory.

Why Does This Matter?

This is a big deal for two reasons:

1. It solves a mystery: It explains how a heart muscle cell knows to build more protein when it stretches. The "tail" of the PC1 protein acts as a sensor on the muscle's skeleton that directly orders the factory to produce more building materials.
2. It's different from heart failure: Usually, when a heart gets too big (hypertrophy), it turns on "bad" genes that lead to failure. This study shows that the PC1 tail triggers a "clean" growth signal focused on making proteins, without immediately triggering the "bad" disease genes.

In a nutshell:
The heart has a built-in sensor (PC1) that sits right on the muscle's framework. When the heart stretches, this sensor flips a switch that tells the cell's protein factory, "We need more parts, let's build!" It does this by taking a direct route through the PI3K-Akt-mTOR highway, ensuring the heart can grow stronger without immediately falling into the trap of disease.

Technical Summary

1. Problem Statement

Pathologic cardiac hypertrophy is a maladaptive response to mechanical stress that drives heart failure. A critical component of this process is the upregulation of protein synthesis. While Polycystin-1 (PC1), encoded by PKD1, has been proposed as a mechanosensor linking membrane stretch to cardiomyocyte growth, the specific subcellular localization of its C-terminal tail (PC1-CT) and its downstream signaling mechanisms in human cardiomyocytes remain poorly defined. Previous studies in rodent models suggested PC1-CT promotes hypertrophy and stabilizes L-type Ca²⁺ channels, but the precise molecular pathways and whether this occurs via canonical hypertrophic gene programs or alternative translational control mechanisms were unclear.

2. Methodology

The study utilized a multi-modal approach combining human and murine models, transcriptomics, and pharmacological inhibition:

• Cell Models:
  • Human: Human induced pluripotent stem cell-derived ventricular cardiomyocytes (hiPSC-CMs), differentiated and matured using triiodothyronine and dexamethasone.
  • Murine: Primary adult mouse ventricular myocytes (isolated via enzymatic digestion).
• Genetic Manipulation:
  • Overexpression: Adenoviral vectors (MOI 10) expressing the PC1 C-terminal fragment (amino acids 4102–4303) fused to V5/mCherry tags, compared against LacZ controls.
  • Knockdown: siRNA targeting PKD1 to validate antibody specificity for endogenous PC1-CT.
• Imaging & Localization:
  • Immunofluorescence confocal microscopy to map PC1-CT localization relative to sarcomeric markers (α-actinin, desmin) and the sarco-endoplasmic reticulum (KDEL).
  • Intensity profile analysis using Python scripts to quantify striation patterns.
• Transcriptomics (RNA-seq):
  • Performed on hiPSC-CMs 48 hours post-infection.
  • Analysis included Differential Expression (DESeq2) and Gene Set Enrichment Analysis (GSEA) using GO Biological Processes.
  • Pathway inference using PROGENy (via decoupleR) to estimate upstream kinase activity.
• Protein Signaling Analysis:
  • Western blotting to assess phosphorylation states of key signaling nodes: Akt, ERK, S6K1, S6, and 4EBP1.
• Pharmacological Inhibition:
  • PI3K: LY294002 (pan-PI3K inhibitor).
  • MEK: U0126.
  • Gi/o signaling: Pertussis toxin.
  • Tyrosine Kinase: Genistein.
  • PI3Kγ: Duvelisib and AS-605240.

3. Key Contributions

• Subcellular Localization: The study identifies a striated, sarcomeric pool of endogenous PC1-CT in human cardiomyocytes, distinct from the sarco-endoplasmic reticulum.
• Maturation-Dependent Distribution: It reveals that PC1-CT localization shifts with maturation: in hiPSC-CMs, it localizes between α-actinin bands, whereas in adult cardiomyocytes, it colocalizes with α-actinin and desmin (Z-discs).
• Signaling Specificity: The authors demonstrate that PC1-CT drives protein synthesis via a PI3K-Akt-mTOR-S6K1-S6 axis without activating the canonical fetal-gene hypertrophic program.
• Mechanistic Independence: The study clarifies that this specific biosynthetic signaling is independent of Gi/o heterotrimeric G-proteins and PI3Kγ, distinguishing it from previously reported membrane-anchored PC1-CT mechanisms.

4. Results

A. Localization of PC1-CT

• Endogenous Signal: Immunolabeling with a human-specific anti-PC1-CT antibody revealed a regular striated pattern (~1.7 µm periodicity) in hiPSC-CMs. This signal was reduced by siRNA knockdown, confirming specificity.
• Sarcomeric Association: In hiPSC-CMs, PC1-CT localized between α-actinin bands with minimal overlap with the KDEL (ER) marker.
• Maturation Effect: In adult mouse cardiomyocytes, overexpressed PC1-CT colocalized strongly with both α-actinin and desmin, suggesting a maturation-dependent shift in sub-sarcomeric positioning.

B. Transcriptomic Profiling

• Gene Expression: RNA-seq of PC1-CT overexpressing hiPSC-CMs showed significant enrichment in gene sets related to ribosome biogenesis, RNA processing, nuclear export, and protein synthesis.
• Hypertrophic Markers: Classical hypertrophic markers (e.g., Nppa, Nppb, Myh7) remained unchanged, indicating a dissociation between translational upregulation and the canonical hypertrophic transcriptional program.
• Pathway Inference: PROGENy analysis predicted increased PI3K pathway activity.

C. Signaling Pathway Activation

• mTOR Branch Activation: PC1-CT overexpression increased phosphorylation of Akt, ERK, S6K1, and Ribosomal Protein S6.
• Selective Activation: Notably, phosphorylation of 4EBP1 (the other major mTORC1 effector) was unchanged. This suggests PC1-CT preferentially activates the S6K1-S6 branch of mTOR signaling.
• Upstream Dependency:
  • PI3K: Treatment with LY294002 (PI3K inhibitor) abolished S6 phosphorylation.
  • MEK: Treatment with U0126 (MEK inhibitor) had no effect on S6 phosphorylation.
  • Gi/o Independence: Pertussis toxin (Gi/o inhibitor) and PI3Kγ-selective inhibitors (Duvelisib, AS-605240) did not block PC1-CT-induced Akt or S6 phosphorylation.

5. Significance and Implications

• Novel Mechanosensing Mechanism: This work establishes that PC1-CT acts as a mechanosensor that directly engages the PI3K-Akt-mTOR-S6K1-S6 pathway to enhance ribosome biogenesis and protein synthesis in human cardiomyocytes.
• Dissociation of Growth Programs: The findings reveal that cardiomyocyte growth can be driven by translational control (ribosome biogenesis) without triggering the fetal-gene transcriptional program typically associated with pathological hypertrophy.
• Therapeutic Context: Understanding that PC1-CT signaling is Gi/o-independent in this context challenges previous models derived from membrane-anchored constructs. This distinction is crucial for developing therapies targeting PC1-related signaling in cardiac hypertrophy or Polycystic Kidney Disease (PKD), where PKD1 and TSC2 (a negative regulator of mTOR) are often co-deleted.
• Future Directions: The study highlights the need to define the precise sub-sarcomeric binding partners of PC1-CT and determine how mechanical stress modulates this specific biosynthetic pathway in vivo.